Emerging innovations in cold plasma therapy against cancer: A paradigm shift

Dubey, Sunil Kumar; Dabholkar, Neha; Pal, Udit Narayan; Singhvi, Gautam; Sharma, Navin Kumar; Puri, Anu; Kesharwani, Prashant

doi:10.1016/j.drudis.2022.05.014

Cited by 24 publications

(9 citation statements)

References 147 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CAP has been applied in a wide range of industries, including medicine and in particular, in cancer therapy; CAP has shown promising results in destroying cancer cells as well as solid tumors by affecting various related mechanisms at the same time, such as inducing apoptosis, specifically in tumor cells but not in their normal counterparts, reducing cell migration, arresting the cell cycle at the S-phase, damaging the DNA, along with increasing the intracellular concentrations of ROS in the TME, reducing tumor immunosuppression, and improving antigenicity [447][448][449][450][451][452][453]. CAP has gained FDA approval to be used in cancer therapy [454][455][456]. However, this technology has not been used in cancer vaccine development yet.…”

Section: Combining Artificial Intelligence and Cold Plasma Technology...mentioning

confidence: 99%

Recent Findings on Therapeutic Cancer Vaccines: An Updated Review

Sheikhlary,

Lopez,

Moghimi

et al. 2024

Biomolecules

View full text Add to dashboard Cite

Cancer remains one of the global leading causes of death and various vaccines have been developed over the years against it, including cell-based, nucleic acid-based, and viral-based cancer vaccines. Although many vaccines have been effective in in vivo and clinical studies and some have been FDA-approved, there are major limitations to overcome: (1) developing one universal vaccine for a specific cancer is difficult, as tumors with different antigens are different for different individuals, (2) the tumor antigens may be similar to the body’s own antigens, and (3) there is the possibility of cancer recurrence. Therefore, developing personalized cancer vaccines with the ability to distinguish between the tumor and the body’s antigens is indispensable. This paper provides a comprehensive review of different types of cancer vaccines and highlights important factors necessary for developing efficient cancer vaccines. Moreover, the application of other technologies in cancer therapy is discussed. Finally, several insights and conclusions are presented, such as the possibility of using cold plasma and cancer stem cells in developing future cancer vaccines, to tackle the major limitations in the cancer vaccine developmental process.

show abstract

Section: Combining Artificial Intelligence and Cold Plasma Technology...mentioning

confidence: 99%

Recent Findings on Therapeutic Cancer Vaccines: An Updated Review

Sheikhlary,

Lopez,

Moghimi

et al. 2024

Biomolecules

View full text Add to dashboard Cite

show abstract

“…13 Dielectric barrier discharge (DBD) and atmospheric pressure plasma jet (APPJ) 14 are recognized as the most common and important sources of CAP in medical applications such as sterilization, 15 wound healing, 16,17 dentistry, 18 destroying microorganisms, 19 and cancer therapy. 20 Lately, transferred cold atmospheric plasma (TCAP) has become a prominent technique for producing CAP. 21 In this method, an APPJ is ignited as transferred plasma from an ignited primary CAP source, such as a dielectric barrier discharge at the downstream terminal of a thin, lengthy plastic pipe.…”

Section: Introductionmentioning

confidence: 99%

A Two-Stage Transferred Cold Atmospheric Plasma as a Unique Therapeutic Strategy for Targeting Colon Cancer Stem Cells

Soulat,

mohsenpour,

Roshangar

et al. 2024

Adv Pharm Bull

View full text Add to dashboard Cite

The study examines the induction of apoptosis in colon cancer stem cells (CCSCs) within a 3D culture setting, employing an innovative cold atmospheric plasma (CAP) transmission method known as TS-TCAP. TS-TCAP is a partially or fully ionized non-thermal gaseous mixture that comprises photons, charged and neutral particles, and free radicals, which has gained traction in biomedical applications such as cancer therapy. TS-TCAP impacts CCSCs via a continuous, two-step transport process, facilitating the efficient delivery of reactive oxygen and nitrogen species (RONS). The key cellular factors of CCSCs impacted by TS-TCAP treatment, encompassing the secretion and expression levels of IL-6 and IL-8, apoptotic cell count, and expression of BAX, BCL-2, and KI-67 proteins, were evaluated using qrt-ELISA, Annexin V, and qrt-PCR procedures, respectively. The outcomes of CCSCs treatment with TS-TCAP reveal a notable rise in the number of apoptotic cells (p value <0.0001), diminished secretion, and gene expression of IL-6 and IL-8 (p-value < 0.0001), accompanied by favorable alterations in BCL-2 and BAX gene expression (p value <0.0001). Additionally, a notable decrease in KI-67 expression was observed, correlating with a reduction in CCSCs proliferation (p value <0.0001). As well, this study underscores the anti-cancer potential of TS-TCAP, showcasing its efficacy in reducing CCSCs survival rates. However, further pre-clinical and clinical trials are necessary to evaluate CAP's efficacy, safety, and potential synergistic effects with other therapies thoroughly. Overall, TS-TCAP presents a promising alternative for CCSCs treatment, pending further investigation and refinement.

show abstract

“…For decades, NTAPP was used to treat different cancers and tumors [ 9 , 10 , 11 ]. It is now well known that the ROS/RNS played an important role in the biomedical application of NTAPP [ 12 , 13 , 14 , 15 , 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Effect of Plasma On-Time with a Fixed Duty Ratio on Reactive Species in Plasma-Treated Medium and Its Significance in Biological Applications

Mumtaz

Rana

Lim

et al. 2023

IJMS

View full text Add to dashboard Cite

Optimizing the therapeutic range of nonthermal atmospheric pressure plasma (NTAPP) for biomedical applications is an active research topic. For the first time, we examined the effect of plasma on-times in this study while keeping the duty ratio and treatment time fixed. We have evaluated the electrical, optical, and soft jet properties for two different duty ratios of 10% and 36%, using the plasma on-times of 25, 50, 75, and 100 ms. Furthermore, the influence of plasma on-time on reactive oxygen and nitrogen species (ROS/RNS) levels in plasma treated medium (PTM) was also investigated. Following treatment, the characteristics of (DMEM media) and PTM (pH, EC, and ORP) were also examined. While EC and ORP rose by raising plasma on-time, pH remained unchanged. Finally, the PTM was used to observe the cell viability and ATP levels in U87-MG brain cancer cells. We found it interesting that, by increasing the plasma on-time, the levels of ROS/RNS dramatically increased in PTM and significantly affected the viability and ATP levels of the U87-MG cell line. The results of this study provide a significant indication of advancement by introducing the optimization of plasma on-time to increase the efficacy of the soft plasma jet for biomedical applications.

show abstract

Emerging innovations in cold plasma therapy against cancer: A paradigm shift

Cited by 24 publications

References 147 publications

Recent Findings on Therapeutic Cancer Vaccines: An Updated Review

Recent Findings on Therapeutic Cancer Vaccines: An Updated Review

A Two-Stage Transferred Cold Atmospheric Plasma as a Unique Therapeutic Strategy for Targeting Colon Cancer Stem Cells

Effect of Plasma On-Time with a Fixed Duty Ratio on Reactive Species in Plasma-Treated Medium and Its Significance in Biological Applications

Contact Info

Product

Resources

About